| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 81.25 M USD | 44.12 M USD | 36.75 M USD | 25.38 M USD | 35.10 M USD | 34.80 M USD | 14.18 M USD | 19.51 M USD | 22.87 M USD | 16.90 M USD | 11.44 M USD | 5.51 M USD |
| Depreciation & Amortization | 10.42 M USD | 9.67 M USD | 9.52 M USD | 9.43 M USD | 11.07 M USD | 8.39 M USD | 5.42 M USD | 4.32 M USD | 4.05 M USD | 3.59 M USD | 3.39 M USD | 3.33 M USD |
| Stock-Based Compensation | 7.83 M USD | 6.57 M USD | 5.32 M USD | 4.17 M USD | 3.48 M USD | 3.02 M USD | 2.64 M USD | 2.35 M USD | 2.26 M USD | 1.68 M USD | 1.42 M USD | 1.30 M USD |
| Capital Expenditures | 6.78 M USD | 6.96 M USD | 7.26 M USD | 3.23 M USD | 4.88 M USD | 2.98 M USD | 3.76 M USD | 3.05 M USD | 6.42 M USD | 2.84 M USD | 2.27 M USD | 1.17 M USD |
| Cash Flow from Investing | -64.94 M USD | -200.12 M USD | -24.71 M USD | -10.37 M USD | -61.08 M USD | -52.89 M USD | -24.10 M USD | -7.05 M USD | -28.96 M USD | -17.21 M USD | -3.48 M USD | -7.75 M USD |
| Cash Flow from Financing | -14.54 M USD | 158.10 M USD | -7.13 M USD | -9.23 M USD | 13.70 M USD | 32.16 M USD | -4.62 M USD | -4.42 M USD | 80000 USD | -2.58 M USD | 1.08 M USD | 6.66 M USD |
| Dividends Paid | 18.11 M USD | 14.38 M USD | 12.45 M USD | 10.99 M USD | 9.34 M USD | 7.70 M USD | 6.74 M USD | 5.45 M USD | 4.18 M USD | 3.32 M USD | 2.85 M USD | 2.31 M USD |
| Stock Buybacks | 1.82 M USD | 1.72 M USD | 853000 USD | 642000 USD | 802000 USD | 570000 USD | 683000 USD | 741000 USD | 778000 USD | 311000 USD | 266000 USD | 211000 USD |
| Free Cash Flow | 74.47 M USD | 37.16 M USD | 29.49 M USD | 22.15 M USD | 30.22 M USD | 31.82 M USD | 10.42 M USD | 16.45 M USD | 16.45 M USD | 14.05 M USD | 9.16 M USD | 4.34 M USD |
LeMaitre Vascular Inc. develops, manufactures, and markets specialized medical devices and implants designed for vascular surgery and the treatment of peripheral vascular disease. The company offers a comprehensive portfolio of products across six key categories: aortic, arteriovenous access, cardiac, carotid, lower extremity, and neuro applications. Its product lines include allografts—cryopreserved human tissue grafts used in vascular reconstruction—embolectomy catheters for removing blood clots from arteries, thrombectomy catheters for venous thrombi removal, and various synthetic and biologic grafts and patches. LeMaitre also provides human tissue cryopreservation services. The company distributes its products globally through direct sales to hospitals in over 25 countries and through distributors in more than 70 countries across North America, Europe, and Asia-Pacific. Founded in 1986 and headquartered in Burlington, Massachusetts, LeMaitre serves vascular surgeons performing both open surgical procedures and minimally invasive interventions, with the majority of its revenue generated from the United States market.